Abstract
The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.
Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.
Current Topics in Medicinal Chemistry
Title:Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Volume: 17 Issue: 12
Author(s): Jerzy Leszek, Elzbieta Trypka, Vadim V. Tarasov, Ghulam Md Ashraf and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.
Abstract: The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.
Export Options
About this article
Cite this article as:
Leszek Jerzy, Trypka Elzbieta, Tarasov V. Vadim, Ashraf Md Ghulam and Aliev Gjumrakch, Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease, Current Topics in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1568026617666170103163403
DOI https://dx.doi.org/10.2174/1568026617666170103163403 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Bilateral Interrelationship of Diabetes and Periodontium
Current Diabetes Reviews Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Current Vascular Pharmacology Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews Cheminformatics Based Machine Learning Approaches for Assessing Glycolytic Pathway Antagonists of Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Hypomagnesaemia/Hypokalemia Associated with the Use of Esomeprazole
Current Drug Safety Healthcare Management During A Pandemic: The Other Side of the Coin for the Treatment of COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Incretins and Lipid Metabolism
Current Medicinal Chemistry Design and Evaluation of the Effectiveness of a Drug in Adhesive Transdermal Delivery System of Vildagliptin
Drug Delivery Letters The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Modulatory Factors Responsible for Neoangiogenesis in Young Patients with Long-Standing Diabetes Mellitus Type 1
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) HPLC Stability Indicating Assay Method for Metformin Hydrochloride in Bulk Drug and Tablets and Cytotoxicity of Degradation Products
Current Pharmaceutical Analysis Effectiveness of Passion Fruit Peel Flour (Passiflora edulis L.) versus Turmeric Flour (Curcuma longa L.) on Glycemic Control: Systematic Review and Meta-Analysis
Current Diabetes Reviews